Xencor Licenses Xtend™ Antibody Half-life Prolongation Platform to Merck & Co., Inc. Read more about Xencor Licenses Xtend™ Antibody Half-life Prolongation Platform to Merck & Co., Inc.
Xencor to Present Phase 1 Data on XmAb®2513 Antibody for Lymphomas at the American Society of Clinical Oncology Annual Meeting Read more about Xencor to Present Phase 1 Data on XmAb®2513 Antibody for Lymphomas at the American Society of Clinical Oncology Annual Meeting
Xencor Appoints Jeffrey V. Ravetch of The Rockefeller University to its Scientific Advisory Board Read more about Xencor Appoints Jeffrey V. Ravetch of The Rockefeller University to its Scientific Advisory Board
Xencor Licenses Antibody Optimization Technology Read more about Xencor Licenses Antibody Optimization Technology
Xencor Appoints Former ZymoGenetics CEO, Bruce Carter, to Chairman of the Board Read more about Xencor Appoints Former ZymoGenetics CEO, Bruce Carter, to Chairman of the Board
Xencor Receives Milestone Payment from Pfizer Under Antibody Technology License Agreement Read more about Xencor Receives Milestone Payment from Pfizer Under Antibody Technology License Agreement
Data Published in Nature Biotechnology Shows Fc Engineering Improves Antibody Efficacy and Convenience Read more about Data Published in Nature Biotechnology Shows Fc Engineering Improves Antibody Efficacy and Convenience
Xencor Appoints Edgardo Baracchini, Ph.D., to Chief Business Officer Read more about Xencor Appoints Edgardo Baracchini, Ph.D., to Chief Business Officer
MorphoSys and Xencor Sign License and Collaboration Agreement for Clinical Antibody Program Read more about MorphoSys and Xencor Sign License and Collaboration Agreement for Clinical Antibody Program
Xencor Receives Second Milestone Payment from Boehringer Ingelheim Under Antibody Technology License Agreement Read more about Xencor Receives Second Milestone Payment from Boehringer Ingelheim Under Antibody Technology License Agreement
